China: Sinovac Biotech to delist from Nasdaq, enters private deal for $401.8m

China: Sinovac Biotech to delist from Nasdaq, enters private deal for $401.8m

Visual from company website.

Tomas S. Noda III

28 June, 2017

NASDAQSinovac AmalgamationSinovac BiotechSinovac Cayman

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter

Read more from Greater China

Nikkei Logo
DealStreetAsia Logo
About Us
Team
Advertise
Contact
Careers
Blog
Privacy Policy
Terms & Conditions
© Copyright DEALSTREETASIA 2014-2025 All rights reserved.